Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHEK2 | O96017 | 3/20 | 0.41 |
| ▸ | HDAC6 | Q9UBN7 | 9/20 | 0.40 |
| ▸ | HDAC3 | O15379 | 4/20 | 0.39 |
| ▸ | HDAC1 | Q13547 | 4/20 | 0.39 |
| ▸ | HDAC8 | Q9BY41 | 4/20 | 0.39 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.39 |
| ▸ | PLAU | P00749 | 2/20 | 0.39 |
| ▸ | PRSS1 | P07477 | 2/20 | 0.39 |
| ▸ | F2 | P00734 | 1/20 | 0.39 |
| ▸ | F10 | P00742 | 1/20 | 0.39 |
| ▸ | PLG | P00747 | 1/20 | 0.39 |
| ▸ | PLAT | P00750 | 1/20 | 0.39 |
| ▸ | CSNK1D | P48730 | 1/20 | 0.38 |
| ▸ | CSNK1E | P49674 | 1/20 | 0.38 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6511681 | 0.92 | HDAC1 (0.44) | HDAC6HDAC3HDAC1HDAC8HDAC2 | |
| SCHEMBL6503801 | 0.91 | HPSE (0.42) | CHEK2HDAC6HDAC3HDAC1HDAC8 | |
| SCHEMBL6505106 | 0.82 | CHEK2 (0.42) | CHEK2HDAC6HDAC3HDAC1HDAC8 | |
| SCHEMBL6061587 | 0.82 | PLAU (0.54) | CHEK2PLAUPRSS1F2F10 | |
| SCHEMBL6511667 | 0.81 | HDAC6 (0.42) | HDAC6HDAC3HDAC1HDAC8HDAC2 | |
| SCHEMBL6506693 | 0.81 | HDAC1 (0.48) | CHEK2HDAC6HDAC3HDAC1HDAC8 | |
| SCHEMBL6511506 | 0.81 | CHEK2 (0.47) | CHEK2HDAC6HDAC3HDAC1HDAC8 | |
| SCHEMBL6510570 | 0.80 | F2 (0.55) | HDAC6HDAC3HDAC1HDAC8HDAC2 | |
| SCHEMBL6505463 | 0.80 | HDAC6 (0.45) | CHEK2HDAC6HDAC3HDAC1HDAC8 | |
| SCHEMBL1842124 | 0.80 | CHEK2 (0.61) | CHEK2F10CSNK1DCSNK1EMAPK14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050148646-A1 | Dicationic triaryl analogs as anti-protozoan agents | BOYKIN DAVID W (US) | 2005-07-07 | — | — | US | claimed |
| US-20050148646-A1 | Dicationic triaryl analogs as anti-protozoan agents | BOYKIN DAVID W (US) | 2005-07-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050148646-A1 | Dicationic triaryl analogs as anti-protozoan agents | DDT, DDC, DARS1 | CHEK2 2931/4885HDAC6 466/4885HDAC3 86/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.